文献速递肝肾功能剂量调整药物不良反应与药物警戒

药物相关急性肾损伤的经济负担与肾毒素管理策略的成本节约:系统综述

A Systematic Review of the Costs of Drug-Associated Acute Kidney Injury and Potential Cost Savings With Nephrotoxin Stewardship Prevention Strategies.
PubMed 文献 · Clin Pharmacol Ther · 2024-11-13

There is a scarcity of information related to the financial impact of acute kidney injury (AKI), and even more so the economics of drug-associated AKI (D-AKI).…

要点

  • D-AKI显著增加住院费用,总入院费用可达47,696至173,569美元。
  • 肾毒素管理策略可节约总医疗费用5,171至364,973美元。
  • 每患者日费用节约范围为17至942美元。

核心结论

  • D-AKI的院内经济影响显著,实施肾毒素管理策略以减少D-AKI与成本节约相关。
  • 机构应采用高效的战略性肾毒素管理计划以优化患者护理并降低成本。

研究设计与样本

  • 主要结局包括AKI发生率、资源使用以及肾毒素管理计划/D-AKI事件或无事件的成本。
  • 所有成本均调整为2023年美元(USD2023)。

主要发现

  • 8项研究比较了D-AKI与无AKI的成本,D-AKI患者的总入院费用范围为47,696至173,569美元。
  • 预防策略的总医疗费用节约范围为5,171至364,973美元,每患者日总费用节约范围为17至942美元。

临床怎么用

  • 临床可参考D-AKI相关费用数据,推动机构建立肾毒素管理策略以降低D-AKI发生并节约成本。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

There is a scarcity of information related to the financial impact of acute kidney injury (AKI), and even more so the economics of drug-associated AKI (D-AKI). Our goal was to provide a comprehensive summary of the economic burden of D-AKI by evaluating the costs of D-AKI compared to not developing AKI and cost savings associated with nephrotoxin stewardship approaches. Following the PRISMA guidelines, a literature search was conducted using PubMed to identify articles from database inception through November 2023. The main outcomes included AKI incidence, resource use, and cost of nephrotoxin stewardship programs/D-AKI event or no event. Key findings were summarized based on whether the study compared the cost of D-AKI vs. no AKI or identified potential cost savings associated with a nephrotoxin stewardship method to prevent D-AKI or worsening D-AKI. All costs were adjusted to USD2023. Twenty-five studies met the inclusion criteria. Eight studies compared the cost of D-AKI to no AKI. Total admission costs of patients who developed D-AKI ranged from $47,696 to $173,569. Nineteen studies implemented nephrotoxin stewardship with 12 substituting a less nephrotoxic drug; five using therapeutic drug monitoring and two altering drug dosing to limit exposure. Overall, these prevention strategies ranged from $5,171 to $364,973 in total medical cost savings and $17 to $942 in total cost savings per patient-day. The in-hospital economic impact of D-AKI is substantial. Implementing nephrotoxin stewardship strategies to reduce D-AKI is associated with cost savings. Institutions should adopt strategic and efficient nephrotoxin stewardship programs to optimize patient care and reduce costs.

来源:Clin Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Stottlemyer BA, Tran T, Suh K, et al. A Systematic Review of the Costs of Drug-Associated Acute Kidney Injury and Potential Cost Savings With Nephrotoxin Stewardship Prevention Strategies. Clin Pharmacol Ther. 2024. PMID: 39535321. doi:10.1002/cpt.3493

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。